Palla Pharma Limited, a vertically integrated pharmaceutical company, produces and distributes narcotic raw materials, active pharmaceutical ingredients, and finished dosage formulations for pharmaceutical markets in Australia and Norway.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.34|
|52 Week High||AU$0.23|
|52 Week Low||AU$0.88|
|1 Month Change||28.30%|
|3 Month Change||-8.11%|
|1 Year Change||-52.78%|
|3 Year Change||-75.89%|
|5 Year Change||-89.27%|
|Change since IPO||-91.28%|
Recent News & Updates
Auditors Have Doubts About Palla Pharma (ASX:PAL)
The harsh reality for Palla Pharma Limited ( ASX:PAL ) shareholders is that its auditors, KPMG LLP - Klynveld Peat...
Palla Pharma's (ASX:PAL) Shareholders Are Down 82% On Their Shares
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Spare a thought for...
|PAL||AU Life Sciences||AU Market|
Return vs Industry: PAL underperformed the Australian Life Sciences industry which returned 4.9% over the past year.
Return vs Market: PAL underperformed the Australian Market which returned 21.1% over the past year.
Stable Share Price: PAL is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: PAL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Palla Pharma Limited, a vertically integrated pharmaceutical company, produces and distributes narcotic raw materials, active pharmaceutical ingredients, and finished dosage formulations for pharmaceutical markets in Australia and Norway. It also produces and distributes poppy seeds to culinary markets. The company was formerly known as TPI Enterprises Limited and changed its name to Palla Pharma Limited in June 2019.
Palla Pharma Fundamentals Summary
|PAL fundamental statistics|
Is PAL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PAL income statement (TTM)|
|Cost of Revenue||AU$34.71m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.36|
|Net Profit Margin||-351.48%|
How did PAL perform over the long term?See historical performance and comparison
Is Palla Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PAL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PAL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PAL is unprofitable, so we can't compare its PE Ratio to the Global Life Sciences industry average.
PE vs Market: PAL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PAL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PAL is good value based on its PB Ratio (2.7x) compared to the AU Life Sciences industry average (5x).
How is Palla Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PAL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: PAL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PAL's is expected to become profitable in the next 3 years.
Revenue vs Market: PAL's revenue (64.7% per year) is forecast to grow faster than the Australian market (5.4% per year).
High Growth Revenue: PAL's revenue (64.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PAL's Return on Equity is forecast to be high in 3 years time
How has Palla Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PAL is currently unprofitable.
Growing Profit Margin: PAL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PAL is unprofitable, and losses have increased over the past 5 years at a rate of 20.3% per year.
Accelerating Growth: Unable to compare PAL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PAL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (59.8%).
Return on Equity
High ROE: PAL has a negative Return on Equity (-293.25%), as it is currently unprofitable.
How is Palla Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: PAL's short term assets (A$30.7M) exceed its short term liabilities (A$28.1M).
Long Term Liabilities: PAL's short term assets (A$30.7M) exceed its long term liabilities (A$1.7M).
Debt to Equity History and Analysis
Debt Level: PAL's debt to equity ratio (75%) is considered high.
Reducing Debt: PAL's debt to equity ratio has reduced from 130.3% to 75% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PAL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: PAL has less than a year of cash runway if free cash flow continues to grow at historical rates of 5.9% each year.
What is Palla Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PAL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PAL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PAL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PAL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PAL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Giles Moss serves as Vice President and General Manager of Europe at GW Pharmaceuticals. He has been central to the rapid successful ex-US launch of a new highly regulated orphan medicine for epilepsy....
Experienced Management: PAL's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Experienced Board: PAL's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.6%.
Palla Pharma Limited's employee growth, exchange listings and data sources
- Name: Palla Pharma Limited
- Ticker: PAL
- Exchange: ASX
- Founded: 2004
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$55.051m
- Shares outstanding: 161.91m
- Website: https://www.pallapharma.com
- Palla Pharma Limited
- Tower 4
- 727 Collins Street
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 18:18|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.